What is Broken String Biosciences?
Broken String Biosciences is a United Kingdom-based genomics company dedicated to building a sophisticated technology platform. This platform is designed to accelerate the development of cell and gene therapies, a rapidly advancing field within biotechnology. By focusing on foundational genomics technology, the company aims to provide critical tools and insights necessary for researchers and developers in the therapeutic space.
How much funding has Broken String Biosciences raised?
Broken String Biosciences has raised a total of $15M across 1 funding round:
Series A
$15M
Series A (2023): $15M with participation from Illumina Ventures, Heran Partners, Tencent, and Mérieux Equity Partners
Key Investors in Broken String Biosciences
Illumina Ventures
Illumina Ventures is a venture capital firm specializing in genomics and precision health, aiming to foster innovation in life sciences and biopharmaceutical drug development.
Heran Partners
Heran Partners is a Belgium-based investor focused on transformative impacts in healthcare and life sciences, supporting innovative companies with capital and expertise.
Tencent
Tencent is a global technology conglomerate providing internet and mobile services, including online games and applications, with a significant presence in various digital sectors.
What's next for Broken String Biosciences?
The substantial enterprise-level funding, particularly the recent major strategic investment, positions Broken String Biosciences for significant expansion and innovation. This capital infusion is expected to fuel further research and development, enhance the company's platform capabilities, and potentially broaden its market reach. The company is likely to focus on scaling its operations and solidifying its position as a key enabler in the cell and gene therapy ecosystem, attracting further investment and partnerships as it progresses through its growth trajectory.
See full Broken String Biosciences company page
